Eye Disease & Ophthalmology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This Phase 3 study explores a new implantable device that delivers ranibizumab directly into the eye for people with neovascular age-related macular degeneration. The goal is to reduce how often patients need eye injections, which can be uncomfortable and require frequent clinic visits. If the system works as hoped, it could make long-term treatment easier and more convenient for many patients.

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

This Phase 4 study focuses on how well faricimab works in adults with diabetic macular edema, especially in groups that have been underrepresented in previous research. By understanding treatment responses in diverse populations, this study aims to improve vision care options for a wider range of patients. Results from this study will provide important insights after about one year of treatment.

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

This Phase 3 trial is testing a gene therapy called RGX-314 for people with wet age-related macular degeneration. Unlike regular eye injections, this treatment is given once and could reduce or eliminate the need for ongoing injections. If effective, this therapy may significantly ease the burden of treatment for patients living with this eye disease.

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

This Phase 3 trial investigates a gene therapy aimed at improving vision in patients aged 6 and older who have X-linked retinoschisis, a rare inherited eye condition. By targeting the root genetic cause, this treatment has the potential to restore or preserve vision, offering hope for an eye disorder that currently has limited options. The study is actively recruiting participants in the United States.

A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD

This Phase 3 trial compares botulinum toxin A injections to traditional strabismus surgery in children with esotropia, a condition where the eyes turn inward. A successful outcome could provide a less invasive alternative to surgery, reducing the risks associated with anesthesia and surgical procedures. The study aims to enroll 244 children but has not yet started recruiting.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.